Multiple Myeloma and Exercise

Abramson Cancer Center at Penn Medicine10 enrolled

Overview

This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further preliminary data on toxicity and pharmacokinetics of high-dose melphalan.

This is a prospective, single-institution, pilot study of a 3 month weight lifting program designed to increase musle hypertrophy prior to starting stem cell collection and receiving high-dose melphalan, in patients with multiple myeloma. We will use this exercise intervention while patients are receiving initial induction chemotherapy in the 3-6 month period before they receiv high-dose melphalan. The primary study endpoint is to determine the feasibility of recruiting and retaining multiple myeloma patients to an exercise intervention trial. The secondary study endpoint is to determine whether the weight lifting program increases lean body mass as intended.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

Weight Lifting ExercisesOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed multiple myeloma * 1 year since start of treatment for myeloma * Patient and treating physician in agreement to proceed with autologous transplant, with a planned time betwwen study enrollment and transplant of 10 weeks * Age 18 years. * Able to walk for 6 minutes unaided. * Body mass index 50 kg/m2 * Serum creatinine 2.5 mg/dL * Ability to understand the informed consent document and willingness to consent. Written informed consent must be obtained from all patients before study entry. Exclusion Criteria: * Recent (in the past 6 months) participation in progressive weight lifting exercises or who already exercise regulary (3 times a week of moderate intensity aerobic exercise). * Plan to move out of the area during the study intervention. * A psychological, social, or logistical barrier that the principal investigators feel would preclude completion of the study protocol. * Plan for use of any anti-myeloma treatment other than melphalan (the use of total body irradiation will NOT

Locations (1)

Abramson Cancer Center of the Unviersity of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Number of Adverse Events

Time frame: 3-6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.